CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

Caribou Biosciences (CRBU) reported better-than-expected earnings in the first quarter, with top and bottom-line beats.

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 ---- Advancing four clinical programs for ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Every year, we hold a STAT Madness tournament to find the best ...

CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

The author is looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing.

A panel discussion at the Global Life Science Partnering and Investor Conference discusses various strategies and trends in ...

Synvect, Inc., a biotechnology startup pioneering next-generation vector control solutions, has raised a $3M Seed Round from prominent investors, including the Bill & Melinda Gates Foundation, Antler, ...